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INTRODUCTION 1
Thoracic aortic dissection is a life-threatening condition, responsible for 15,000 deaths a year 2 in the United States. 1 Up to 25% of patients presenting with a thoracic aortic aneurysm and 3 dissection have an underlying genetic predisposition, 2, 3 which can be associated with syndromic 4 features , such as Marfan syndrome or Loeys-Dietz syndrome, or not associated with syndromic 5 features, as with PRKG1 and MYH11 mutations. 4 Variants in many genes, including FBN1, ACTA2 6 and SMAD3, among others, can lead to either syndromic or non-syndromic thoracic aortic 7 aneurysm and dissection. 5 Recent advances in the field have shown definitive and strong evidence 8 to support the role of pathogenic variants in ACTA2, COL3A1, FBN1, MYH11, SMAD3, TGFB2, 9 TGFBR1, TGFBR2, MYLK, LOX, and PRKG1 5 as predisposing to hereditary thoracic aortic 10 disease. 3 
11
These genetic findings play a critical role for the patient and family members, helping to guide 12 clinical decision-making to prevent or lessen the impact of a life-threatening thoracic aortic event . 13 Aortic diameter is a central criterion when deciding prophylactic surgical intervention, and the 14 recommended aortic diameter for surgical intervention differs for those with and without an 15 underlying genetic predisposition. The American Heart Association/American College of 16
Cardiology (AHA/ACC) guidelines 6 recommend that patients with genetically mediated 17 aneurysms undergo elective surgical repair at an ascending aortic diameter of 4.0-5.0 cm, 18 depending on the condition; whereas patients without a known genetic mutation undergo elective 19 surgical repair when the sinus or ascending aortic diameter is ≥ 5.5 cm. Recent work shows that 20 different genes predisposing to hereditary thoracic aortic dissection have varying presentations and 21 courses. 7, 8 For instance, patients with ACTA2 mutations more often present with acute aortic 22 dissections whereas patients with Marfan syndrome often present with skeletal and ocular features 23 before aortic dilation is discovered. 9 
24
When a patient presents with a thoracic aortic dissection, it is commonly unknown whether the 1 patient has an underlying rare genetic variant triggering the dissection. The identification of 2 variants known to predispose to thoracic aortic dissection has the potential to improve clinical 3 management and guide treatment strategies for patients and family members. The objective of this 4 study is to examine the utility of research-level whole exome sequencing in patients with a history 5 of thoracic aortic dissection or rupture, as well as to identify which patients and corresponding 6 family members may be most likely to benefit from clinic genetic testing. 7 8 METHODS 9
Study Design 10
The Cardiovascular Health Improvement Project (CHIP) is a biorepository with a historical 11 collection of phenotype data, family history, DNA, genotypes, and aortic tissue samples from 12 participants with aortic disease. Between August 2013 and December 2015, 1752 participants were 13 enrolled in the CHIP biorepository, and of those, 265 cases had a diagnosis of thoracic aortic 14 dissection including type A or type B aortic dissection or aortic rupture with or without aortic 15 aneurysm. Age-, sex-, and ancestry-matched controls (n=265) were identified as previously 16 described from the Michigan Genomics Initiative (MGI), which is a surgical-based biobank. 10 In 17 brief, we matched thoracic aortic dissection cases from CHIP to MGI controls of the same sex, age 18 range (-5, +10) at time of enrollment, and minimum Euclidean distance as calculated from the first 19 two principal components of genotype data indicative of genetic ancestry. Principal components 20 were obtained by principal component analysis (PCA) in PLINK 1.9 11 (www.cog-21 genomics.org/plink/1.9) on 58,563 genotyped variants with > 0.05 minor allele frequency. For 83 22 CHIP samples without genotypes from a customized Illumina HumanCoreExome v12.1 bead 23 array, we used self-reported ancestry instead of principal component-based ancestry to identify 24 controls with similar genetic ancestry. In the event that insufficient DNA was available for the best 1 matched control, we moved sequentially through the top 10 best matched controls. All study 2 procedures were approved by the Institutional Review Board (HUM00052866 and 3 HUM00094409 DNA from whole blood was isolated using the Gentra Puregene Blood kit (Qiagen) following 21 the manufacturer's protocol with reagent volumes scaled to whole blood input of 7.5 ml. DNA 22 samples for cases and controls (n=530) were prepared for whole exome sequencing as outlined by 23 the Northwest Genomics Center (NWGC, University of Washington) as follows: (1) plated on 96-24 well barcoded plates (plates provided by NWGC) with foil plate seals after the plate manifest had 1 been approval, (2) at least 4 micrograms of high-quality genomic DNA was plated per sample, and 2
(3) all DNA samples were normalized to a concentration between 80 to 100 nanograms per 3 microliter (a total volume of at least 50 microliters per sample) and suspended in 1xTE solution 4 (10mM Tris-HCL, pH 8.0, 0.1mM EDTA, pH 8.0) and quantitated using the Quant-iT PicoGreen 5 dsDNA kit (Invitrogen). quality control/assurance of DNA samples. Samples have a detailed sample manifest (i.e., 10 identification number/code, sex, DNA concentration, barcode, extraction method). Initial quality 11 control entails DNA quantification, sex-typing and molecular fingerprinting using a high 12 frequency, cosmopolitan genotyping assay. This fingerprint is used to identify potential sample 13
handling errors and provides a unique genetic ID for each sample, which eliminates the possibility 14 of sample assignment errors. Samples are failed if: (1) the total amount, concentration or integrity 15 of DNA is too low; (2) the fingerprint assay produces poor genotype data or (3) sex-typing is 16 inconsistent with the sample manifest. 530 samples were submitted to NWGC for whole exome 17 sequencing and 528 were approved for sequencing with sufficient DNA quantity. 18
Library Production, Exome Capture, Sequencing: Library construction and exome capture have 19 been automated (Perkin-Elmer Janus II) in 96-well plate format. 1 ug of genomic DNA was 20 subjected to a series of shotgun library construction steps, including fragmentation through 21 acoustic sonication (Covaris), end-polishing, A-tailing and ligation of sequencing adaptors with 22 dual 8 bp barcodes for multiplexing, followed by PCR amplification. Libraries underwent exome 23 capture using Roche/Nimblegen SeqCap EZ v2.0 (~36.5 MB target). Prior to sequencing, the 24 library concentration was determined by fluorometric assay and molecular weight distributions 1 verified on the Agilent Bioanalyzer (consistently 150 ± 15 bp). format [VCF]) as "raw" calls that contain individual genotype data for one or multiple samples. 14 NWGC applied hard filtering on the "raw" VCF to generate a filtered VCF call set (GATK v3.4). 15
Data Analysis Quality Control: Data quality control included an assessment of: (1) total reads 16 (minimum of 40 million PE75 reads); (2) library complexity (3) capture efficiency (4) coverage 17 distribution: 90% at 8X required for completion; (5) capture uniformity; (6) raw error rates; (7) 18 Transition/Transversion ratio (Ti/Tv); (8) distribution of known and novel variants relative to 19 dbSNP (9) fingerprint concordance > 99%; (10) sample homozygosity and heterozygosity and (11) 20 sample contamination validation. Exome completion was defined as having > 90% of the exome 21 target at > 8X coverage and >80% of the exome target at > 20X coverage. Typically this requires 22 mean coverage of the target at 30-60X. A total of 521 samples, 260 cases and 261 controls, and 23 323,867 variants (single nucleotide polymorphisms and insertion/deletions) passed quality control 1 and were released to researchers. 2 3
Additional sample and variant filtering 4
Bi-allelic sites were extracted and lower coverage genotypes with depth (DP) < 5 were masked 5 out. All samples met the quality control threshold of an individual level call rate > 0.9. Poor quality 6 sites with site-level call rate < 0.9 were excluded. Variants significantly deviating from HWE with 7 p-value < 1x10 -6 were also removed. KING 13 was used to identify five sample pairs as duplicates, 8 and the sample with the lowest call rate was excluded, leaving 258 cases and 258 controls. 9
Concordance with Exome+GWAS array genotypes was > 0.999 across all minor allele 10 frequencies. After review of the medical record nine cases were excluded for traumatic aortic 11 dissection (i.e, accident or illicit drug use) and nine for abdominal aorta rupture as the etiology of 12 disease is typically atherosclerotic in nature. The final analysis set was comprised of 240 cases and 13 258 controls and 299,195 variants. We opted to keep all cases and controls that passed quality 14 control procedures, rather than reduce the sample size by only including complete pairs. 15
16

Annotation of variants with a clinical impact 17
We focused on the following genes which confer a dominantly inherited risk for aortic 18 dissection and with definitive and strong evidence of association of hereditary thoracic aortic 19 aneurysm and dissection: ACTA2, COL3A1, FBN1, MYH11, SMAD3, TGFB2, TGFBR1, TGFBR2, 20 MYLK, LOX, and PRKG1 5, 14 . A total of 248 variants in these genes were annotated using 21 dbNSFPv3.5a. and reviewed by a single researcher blinded to case or control status of the sample 22 in which the variant was identified. Variants were then annotated as pathogenic, variants of 23 unknown significance, or benign. Protein isoforms that are major isoforms expressed in smooth 24 muscle cells (SMC) or used in previous publications were used to predict amino acid changes 1 ( Supplementary Table 1 ). To define pathogenic variants, we annotated variants based on the 2 ACMG-AMP standards and guidelines. 15 Additionally, established rules 14 were used to classify 3 rare variants as pathogenic or disease-causing. Rare variants were annotated as variants of 4 unknown significance if lacking proof of pathogenicity. Variants were considered benign if they 5 are nonsynonymous mutations with MAF ≥ 0.005 in ExAC Non-Finnish Europeans 16 or in a 6 nonrelevant isoform, were synonymous mutations, or occurred > ±2 bp from intron/exon 7 boundaries. 8 9
Molecular Inversion Probe Sequencing 10
Molecular Inversion Probe Sequencing (MIPS) was performed as a technical replicate of cases 11 and controls that were whole exome sequenced and found to carry a pathogenic variant. MIPS was 12 first performed on DNA from the same extraction used for whole exome sequencing. An additional 13 round of MIPS was performed from a second DNA isolation to serve as a sample replicate. A 14 custom targeted sequencing panel was designed for 116 genes using single molecule molecular 15 inversion probes or smMIPS. 17 Coding exon coordinates were retrieved from the UCSC Genome 16
Browser "knownGene" table (build GRCh37/hg19) and padded by 5 bp in each direction to include 17 splice sites. Probes were designed and prepared as previously described. 18 Briefly, probe sequences 18 unique to each targeted region were selected using custom Python scripts, and synthesized in batch 19 as a microarray of 150mers (CustomArray, Inc). Probes were designed with identical adaptor 20 sequences and were amplified with PCR using primers directed to those sequences. Adaptors were 21 removed by overnight digestion with EarI (NEB), purified with one volume SPRI beads 22 supplemented with five volumes isopropanol, and eluted in Tris-EDTA pH 8. For each sample, 23 approximately 9 ng of purified smMIPS probes were combined with 250 ng genomic DNA, in a 24 reaction mixture including Ampligase DNA Ligase Buffer 1X (Epicentre), 0.4 uM dNTPs (NEB), 1 3.2U HemoKlentaq (NEB) and 1U Ampligase (Epicentre). After denaturation at 95ºC for 10 2 minutes and incubation at 60ºC for 20 hours, linear probes and the remaining genomic DNA were 3 removed by exonuclease treatment with ExoI and ExoII (NEB). The captured material was 4 amplified by PCR using barcoded primers. The resulting PCR products were pooled for one lane 5 of paired-end 150 bp sequencing on an Illumina HiSeq 4000 instrument at the University of 6
Michigan Sequencing Core. Reads were aligned to the human genome reference (build 7 GRCh37/hg19) using bwa mem 19 and a custom pipeline (available at 8 https://github.com/kitzmanlab/mimips) was used to remove smMIPS probe arm sequences and 9 remove reads with duplicated molecular tags. 10
Variant calling of MIPS sequencing results for both single nucleotide variants and 11 insertions/deletions was performed using the GotCloud 20 pipeline. All sequencing results were 12 aligned to build GRCh37/hg19. An iterative filtering process was performed after variant calling 13 to remove variants with a depth less than 10, then samples with call rates of less than 0.6, followed 14 by variants with a call rate of less than 0.8 and finally samples with call rates below 0.9. 15
16
Statistical analysis for burden of variants in cases and controls 17
To test for association between carriers of a given variant class and case/control status we used 18
Fisher's exact test when any expected cell counts were < 5 and Chi-square test with Yates' 19 continuity correction otherwise. This was done using the statistical programming language R 20 version 3.5.1. We identified first degree relatives using KING2 13 and whole exome sequencing 21 variant calls. For the two first degree relative pairs we found in the cases, we retained the first 22 sample acquired (proband) for the analysis resulting in 238 cases. A sample carrying at least one 23 of a variant class was considered a carrier. We performed burden tests for association with case 24 status across the 11 genes for all pathogenic variants (N=24) and variants of unknown significance 1 (N=86). We first excluded carriers of pathogenic variants before testing for association with case 2 status for carriers of variants of unknown significance (Ncases=213, Ncontrols=258). A Bonferroni 3 threshold of 0.003 is used to account for 17 independent tests, which are assumed to be 4 independent. rupture with or without aortic aneurysm and 258 age-, sex-, and ancestry-matched controls had 17 whole exome sequences available following quality control (see Methods) for quality control 18 failures). For the 498 samples passing quality control, 248 variants were annotated blind to the 19 variant carrier's case or control status. 24 pathogenic variants in 6 genes (COL3A1, FBN1, LOX, 20 PRKG1, SMAD3, TGFBR2) were identified, found exclusively in 26 cases (Table 1) , representing 21 10.8% of cases and 0% of controls. Two variants were seen twice in cases who were first degree 22
relatives. There is a significant burden of pathogenic variants in FBN1 in cases compared to 23 controls (Ncases=18, Ncontrols=0; p-value=2.5x10 -5 , Supplementary Table 2 ). These variants are 24 predominantly found in calcium-binding epidermal growth factor domains of FBN1 (Figure 1) . 25
We examined the proportion of pathogenic variants that were present in commonly used databases 1 and found that of the 24, 11 were present in dbSNP 23 , 8 were listed as pathogenic in ClinVar 24 , 2 and 2 were present in gnomAD 16 ( Supplementary Table 4 ). However, for 9 pathogenic carriers, research-level whole exome 15 sequencing and annotation of pathogenic variants added clinical precision to the current clinical 16 diagnosis ( Table 2 ). 8 of these cases (8/9) lacked a specific clinical diagnosis and research-level 17 whole exome sequencing revealed Marfan syndrome (FBN1, n=4), vascular Ehlers-Danlos 18 syndrome (COL3A1, n=1), or familial thoracic aortic disease (LOX, PRKG1, and SMAD3, n=3). 19
For 1 pathogenic carrier (1/9) there was an incorrect diagnosis of Marfan syndrome, which was 20 revised to Loeys-Dietz syndrome based on a pathogenic variant identified in TGFBR2. In addition, 21 the research-level whole exome sequencing results provide a basis for clinical cascade screening 22 for the family members of all 26 cases (Table 2) . 23
24
Variants of unknown significance 1 86 of the 248 annotated variants in aortopathy genes were annotated as variants of unknown 2 significance. After excluding one of each 1 st degree relative pair (see Methods) and cases with 3 pathogenic variants, 58 of 213 cases (27.2%) and 51 of 258 controls (19.8%) have at least one 4 variant of unknown significance identified from whole exome sequencing, which was not 5 significant (p-value=0.072, Supplementary Table 5 ). There is, however, a significant association 6 between pathogenic variants and cases (p-value=2.8x10 -7 , Supplementary Table 5 ). None of the 7 11 genes demonstrated association between carrier status for variants of unknown significance and 8 thoracic aortic dissection or rupture case/control status ( Supplementary Table 2 ). 9
10
Clinical characteristics between pathogenic variant and non-pathogenic variant carriers 11
The pathogenic carriers were significantly younger (41 vs. 57 years, 77% younger than 50 years 12 old), had significantly more root aneurysms (54% vs. 30%), less hypertension (15% vs. 57%) and 13 less history of smoking (19% vs. 45%) compared to the non-pathogenic carriers. Moreover, the 14 pathogenic carriers had a greater incidence of aortic disease in parents, siblings, and children (all 15 p-values<0.05) (Table 3) . Pathogenic carriers presented with more type A than type B dissections 16 although this comparison was not significant (69.2% vs. 58.9%, p=0.421). Multivariable logistic 17 regression showed that pathogenic carriers were significantly more likely to have dissection age < 18 50 years old, family history of aortic disease, and no history of hypertension (Table 4) . 19 20
DISCUSSION 21
The current study reports our initial experience with research-level whole exome sequencing 22 in patients with thoracic aortic dissection or rupture with or without aneurysm. We tested 240 cases 23 and 258 controls for pathogenic variants in 11 genes known to cause aortic dissection 3 . By whole 24 exome sequencing and validation targeted sequencing, we found pathogenic variants in 10.8% of 1 cases and 0% of controls. 58 (27.2%) cases and 51 (19.8%) controls were identified as carriers of 2 variants of unknown significance. 3
The diagnostic yield of genetic testing of these 11 hereditary thoracic aortic dissection genes 4 in patients with thoracic aortic dissection or rupture could result in a substantial number of patients 5 with improved clinical care. We found a similar yield to that of previous work of identifying 6 pathogenic variants in the same 11 genes (9.3%) based on research exome sequencing of 355 7 patients with an early age onset (≤56 years) of thoracic aortic dissection who had no family history 8 or syndromic features 14 . In contrast, the yield of a whole exome sequencing in 102 thoracic aortic 9 aneurysm and dissection patients was much lower, only 3.9% of the cases had a pathogenic 10 variants in one of 21 genes of interest 25 . This study 25 included patients with thoracic aortic 11 aneurysm or thoracic aortic dissection, in contrast to the more severe phenotype of our study 12 population with thoracic aortic dissection and rupture only. A higher incidence of pathogenic 13 variants in the dissection only cases may reflect the more severe presentation in these patients. The 14 89% of dissection cases that do not have a pathogenic variant may be due to a pathogenic variant 15 currently annotated as a VUS, a pathogenic variant in a gene not yet identified, a high polygenic 16
risk of aortopathy, and/or environmental risk factors. Additional studies of dissection cases may 17 help identify novel genes underlying risk in remaining cases . 18 In the general population, the incidence of pathogenic variants in our 11 genes of interest is 19 very low (1 x 10 -7 %, see Supplementary note). However, in our cohort of patients with aortic 20 dissection and rupture, we identified putative disease causing variants in 11 hereditary thoracic 21 aortic dissection genes in 10.8% of cases, which is consistent with another recently published 22 report 3 and suggests the utility of pursuing a clinical genetic diagnosis in this patient group. The 23 significant risk factors for a pathogenic variant in patients with thoracic aortic dissection or rupture 24 were young age (<50 years old), no history of hypertension, but strong family history of aortic 1 aneurysm, dissection or rupture (especially involving mother, siblings and children) with estimated 2 odds ratios ranging from 5.1 for affected siblings to 6.0 for affected children (Table 4 ). This is in 3 agreement with a recent study in familial and sporadic cases of aneruysm or dissection of the 4 thoracic aorta which demonstrated a significantly increased probability of harboring a pathogenic 5 or likely pathogenic variant in cases which were syndromic, young (age <50), or with a known or 6 probable family history 26 . Patients with pathogenic variants in TGFBR1/2 (Loeys-Dietz 7 syndrome), FBN1 (Marfan syndrome), and MYH11 have a higher risk of aortic dissection and 8 suffer more complications from aortic dissection, including death 6 . Therefore AHA/ACC 9 guideline recommends early and aggressive prophylactic operation to resect the abnormal thoracic 10 aorta in patients with pathogenic variants. 6 Based on our results, we would recommend clinical 11 genetic testing of known hereditary thoracic aortic dissection genes for all aortic dissection and 12 rupture patients, especially those with onset < 50 years old, no history of hypertension, and with 13 a family history of aortic dissection. Once a pathogenic variant is identified in the patients, their 14 family members should undergo screening for the same pathogenic variant. If pathogenic variants 15 are identified in any family members, the clinical management will shift towards close monitoring 16 and potentially early prophylactic resection of diseased aorta as recommended by AHA/ACC 17 guidelines. 6 
18
We did not find a difference in the percentage of variants of unknown significance (VUSs) in 19 11 dissection genes among cases compared to controls (p = 0.07). In constrast, a previous study 20 found a significantly increased burden of VUSs in hereditary thoracic aortic dissection genes in 21 dissection cases < 56 years of age compared with public controls (p = 2 x 10 -8 ). 14 However, several 22 differences in the two studies may have contributed to these different results. The sample size of 23 the control group was substantially higher in the previous study, however the study presented here 24 had sequenced cases and controls in the same batch and performed all quality control and variant 1 annotation blinded to case or control status. Additionally, a focus on younger onset dissection 2 cases may identify higher rates of VUSs that may actually be pathogenic. 27 Although the 2015 3
American College of Medical Genetics guidelines 15 state that "a variant of uncertain significance 4
should not be used in clinical decision-making" we found evidence that variants of unknown 5 significance from CLIA-certified genetic testing resulted in the introduction of syndromic labels 6 and diagnoses into the medical record. For example, a variant of unknown significance in TGFBR2 7 was subsequently described as a "novel change likely causing Loeys-Dietz syndrome." The 8 statistically similar rate of VUS in cases and controls demonstrates the need for greater 9 understanding of the high frequency of VUSs in controls (15% in Guo et al and 20% in this study) 10 and careful interpretation of variants of unknown significance in clinical practice. 11
To address the limitation that our sample processing and whole exome sequencing was not 12
CLIA-certified, we verified pathogenic variants using MIPS. Furthermore, we performed expert-13 annotation of variant pathogenicity blinded to case or control status. This, coupled with the absence 14 of pathogenic variants in controls, provides increased confidence in these results. These 15 precautions lend additional evidence that the research-level whole exome sequencing results are 16 of high enough quality to return findings to patients, which will trigger verification by CLIA-17 certified genetic testing followed by cascade screening for the same pathogenic variant in family 18
members. An EMR review of the cases with a pathogenic variant suggested an average of 4 (3.88) 19
first degree relatives per patient would now be candidates for cascade screening. 20
In conclusion, this work provides evidence that whole exome sequencing and annotation can 21 accurately identify pathogenic variants in established genes for hereditary thoracic aortic 22 dissection in patients with a thoracic aortic dissection or rupture. Moreover, the results highlight 23 meaningful implications for precision health by providing clinical guidance on how to manage 24 both patients and family members. We recommend clinical genetic testing of hereditary thoracic 1 aortic dissection genes in patients who have suffered a thoracic aortic dissection, especially those 2 with onset prior to 50 years old, a family history of aortic dissection or rupture, or no history of 3 hypertension. These clinical genetic test results may help to prevent catastrophic events, such as 4 thoracic aortic dissections and death within family members of pathogenic variant carriers who 5 have a high risk, but have not developed thoracic aortic dissection or rupture. Smoking history was defined as no smoking history versus had a smoking history. Family history 5 was defined as aortic disease noted within a first-degree relative. 6 7 8 
